J Nat Prod. 2018 Mar 23;81(3):579-593. doi: 10.1021/acs.jnatprod.7b00967. Epub 2018 Jan 23.
The taccalonolides are a unique class of microtubule stabilizers isolated from Tacca spp. that have efficacy against drug-resistant tumors. Our previous studies have demonstrated that a C-15 acetoxy taccalonolide, AF, has superior in vivo antitumor efficacy compared to AJ, which bears a C-15 hydroxy group. With the goal of further improving the in vivo efficacy of this class of compounds, we semisynthesized and tested the biological activities of 28 new taccalonolides with monosubstitutions at C-7 or C-15 or disubstitutions at C-7 and C-25, covering a comprehensive range of substituents from formic acid to anthraquinone-2-carbonyl chloride. The resulting taccalonolide analogues with diverse C-7/C-15/C-25 modifications exhibited IC values from 2.4 nM to >20 μM, allowing for extensive in vitro structure-activity evaluations. This semisynthetic strategy was unable to provide a taccalonolide with improved therapeutic window due to hydrolysis of substituents at C-7 or C-15 regardless of size or steric bulk. However, two of the most potent new taccalonolides, bearing isovalerate modifications at C-7 or C-15, demonstrated potent and highly persistent antitumor activity in a drug-resistant xenograft model when administered intratumorally. This study demonstrates that targeted delivery of the taccalonolides to the tumor could be an effective, long-lasting approach to treat drug-resistant tumors.
塔卡醇内酯是一类从塔卡属植物中分离得到的独特的微管稳定剂,对耐药肿瘤具有疗效。我们之前的研究表明,C-15 乙酰氧基塔卡醇内酯 AF 比具有 C-15 羟基的 AJ 具有更好的体内抗肿瘤疗效。为了进一步提高这类化合物的体内疗效,我们半合成并测试了 28 种具有 C-7 或 C-15 单取代或 C-7 和 C-25 双取代的新型塔卡醇内酯的生物活性,涵盖了从甲酸到蒽醌-2-甲酰氯的各种取代基。具有不同 C-7/C-15/C-25 修饰的塔卡醇内酯类似物的 IC 值范围为 2.4 nM 至 >20 μM,允许进行广泛的体外结构-活性评估。由于 C-7 或 C-15 取代基的水解,无论大小或空间位阻如何,这种半合成策略都无法提供具有改善治疗窗口的塔卡醇内酯。然而,两个最有效的新型塔卡醇内酯类似物,在 C-7 或 C-15 处具有异戊酸修饰,当经肿瘤内给药时,在耐药异种移植模型中表现出强大且高度持久的抗肿瘤活性。这项研究表明,将塔卡醇内酯靶向递送至肿瘤可能是一种有效且持久的治疗耐药肿瘤的方法。